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Abstract
Background: APOBEC3G (A3G) and related cytidine deaminases of the APOBEC3 family of proteins are potent inhibitors of
many retroviruses, including HIV-1. Formation of infectious HIV-1 requires the suppression of multiple cytidine deaminases
by Vif. HIV-1 Vif suppresses various APOBEC3 proteins through the common mechanism of recruiting the Cullin5-ElonginB-
ElonginC E3 ubiquitin ligase to induce target protein polyubiquitination and proteasome-mediated degradation. The
domains in Vif and various APOBEC3 proteins required for APOBEC3 recognition and degradation have not been fully
characterized.
Methods and Findings: In the present study, we have demonstrated that the regions of APOBEC3F (A3F) that are required
for its HIV-1-mediated binding and degradation are distinct from those reported for A3G. We found that the C-terminal
cytidine deaminase domain (C-CDD) of A3F alone is sufficient for its interaction with HIV-1 Vif and its Vif-mediated
degradation. We also observed that the domains of HIV-1 Vif that are uniquely required for its functional interaction with
full-length A3F are also required for the degradation of the C-CDD of A3F; in contrast, those Vif domains that are uniquely
required for functional interaction with A3G are not required for the degradation of the C-CDD of A3F. Interestingly, the HIV-
1 Vif domains required for the degradation of A3F are also required for the degradation of A3C and A3DE. On the other
hand, the Vif domains uniquely required for the degradation of A3G are dispensable for the degradation of cytidine
deaminases A3C and A3DE.
Conclusions: Our data suggest that distinct regions of A3F and A3G are targeted by HIV-1 Vif molecules. However, HIV-1 Vif
suppresses A3F, A3C, and A3DE through similar recognition determinants, which are conserved among Vif molecules from
diverse HIV-1 strains. Mapping these determinants may be useful for the design of novel anti-HIV inhibitors.
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Introduction
Human cytidine deaminase apolipoprotein B mRNA-editing
catalytic polypeptide-like 3G (APOBEC3G, A3G) and other
APOBEC3 proteins [1] are related to a family of cytidine
deaminases that also includes apolipoprotein B-editing catalytic
subunit 1 (APOBEC1), APOBEC2, and activation-induced
cytidine deaminase (AID) [2–13]. These proteins, which are
unique to mammals, have cytidine deaminase activities that
modify RNA or DNA. Human APOBEC3 proteins exhibit
varying degrees of inhibitory activity against retroviruses, such as
HIV and SIV [14–22]; endogenous retroviruses [23]; non-LTR
retrotransposons, such as LINE1 [24–31] and Alu [24,25,31,32];
HBV [33–38]; and AAV [26].
In the absence of the Vif protein, APOBEC3 proteins are
packaged into HIV-1 particles through an interaction with Gag
protein molecules [39–45] and the help of cellular 7SL RNA [46]
and/or viral genomic RNA [47,48]. Virion-packaged A3G
mediates cytidine deamination in the viral minus-strand DNA
during new target cell infection [19,21,22,49–52]. Virion-pack-
aged A3G and A3F can also reduce the accumulation of viral
DNA by inhibiting reverse transcription processes [53–59] or
inducing viral DNA degradation [60,61]. In addition, a potent
inhibitory effect of A3G on the formation of proviral DNA has
been described [21,22,55,56]. Whether A3G inhibits HIV-1
mainly through cytidine deamination of viral DNA is still
controversial.
HIV-1 Vif suppresses the activity of multiple human APOBEC3
proteins by assembling a viral-specific E3 ubiquitin ligase through its
interaction with cellular Cullin5 (Cul5)-ElonginB-ElonginC proteins
[62–65]. Vif induces polyubiquitination of APOBEC3 proteins and
tags them for proteasome-mediated degradation [62,63,66–72]. The
carboxyl-terminalBC-box(theSLQxLAmotif)ofHIV-1Vifrecruits
ElonginC and ElonginB [62–64,71], and a highly conserved zinc-
binding Hx5Cx17–18Cx3–5H motif [73–76] and downstream LPx4L
motif in Vif mediate Cul5 association [77].
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3963Various amino-terminal domains of HIV-1 Vif are responsible
for its specificity in recognizing the various APOBEC3 proteins
[13,67,78–83]. For example, the HIV-1 Vif region spanning
amino acids 22 to 44 is important for the suppression of A3G but
not A3F [78,81,82]. In contrast, amino acids 11 to 17 and 74 to 79
are important for the suppression of A3F but not A3G [78–81,83].
A stretch of hydrophobic amino acids 55 to 72 of HIV-1 Vif
(VxIPLx4–5LxWx2YWxL) is critical for both A3G and A3F binding
and suppression [78–81,83]. In addition to A3G and A3F, other
human cytidine deaminases such as A3C and A3DE are also
subject to HIV-1 Vif-induced polyubiquitination and degradation
involving Cul5-ElonginB-ElonginC [72,84]. However, little is
known about how these proteins are recognized by HIV-1 Vif.
In this study, we demonstrate that A3C and A3DE are
recognized by HIV-1 Vif in a fashion similar to that observed
for A3F, distinct from that seen for A3G. The carboxyl-terminal
cytidine deamination domain of A3F alone is sufficient for its
interaction with Vif and Vif-mediated degradation of A3F, and the
requirements for the degradation of full-length A3F are the same
as for its carboxyl-terminal cytidine deamination domain. Thus,
the single cytidine deamination domain of A3C and carboxyl-
terminal cytidine deamination domain of A3F are sufficient for Vif
binding and targeted degradation, in sharp contrast to the
requirement for both the amino- and the carboxyl-terminal
cytidine deamination domains in the case of A3G.
Results
Distinct HIV-1 Vif regions are involved in the suppression
of single-domain cytidine deaminase A3C and double-
domain A3G
Distinct regions of HIV-1 Vif have been found to mediate A3G
or A3F suppression (Fig. 1A); however, the regions of HIV-1 Vif
that are involved in the suppression of other human cytidine
deaminases such as A3C have not been determined. Although
A3C has been shown to have only weak anti-HIV-1 activity in
vitro [16,18], it is efficiently degraded by HIV-1 Vif through the
usage of Cul5-ElonginB-ElonginC E3 ubiquitin ligase. It is
possible that A3C has anti-HIV-1 function in vivo that has to be
neutralized by Vif to allow viral replication. Alternatively, A3C is
recognized by HIV-1 Vif through a similar mechanism as other
potent anti-HIV-1 cytidine deaminases such as A3G or A3F. To
determine whether the previously identified regions of the Vif
protein that are required for A3G or A3F inhibition are also
important for its activity against A3C, we generated a series of
HIV-1 Vif mutant constructs in which critical residues known to
be important for A3G or A3F suppression were mutated (Fig. 1A).
It is well established that A3C is a potent inhibitor [18] of Vif-
deificient simian immunodeficiency virus from African green
monkeys (SIVagm) and is degraded by both SIVagm and HIV-1
Vif [85]. We therefore examined the ability of HIV-1 Vif and the
Figure 1. Effect of mutations in HIV-1 Vif on Vif function. (A) Diagram of the functional domains of HIV-1 Vif. The BC-box structure mediates
the interaction with ElonginB/C. A zinc-binding domain, Hx2YFxCFx4Wx2AWx7-8Cx5H, is important for Cul5 selection. The N-terminal of Vif has been
proposed to bind to APOBEC3 cytidine deaminases. (B) Effect of HIV-1 WT or mutant Vif proteins on the infectivity of SIVagmTangVif in the presence
of A3C. SIV viruses were produced in HEK293T cells co-expressing A3C in the presence of HIV-1 WT or mutant Vif as indicated. Virus infectivity was
assessed by Magi assay, with virus infectivity in the presence of WT Vif set to 100%. Error bars represent the standard deviations from triplicate wells.
(C) Effect of HIV-1 WT or mutant Vif proteins on the infectivity of NL4-3gVif in the presence of A3G. HIV viruses were produced in HEK293T cells co-
expressing A3G in the presence of HIV-1 WT or mutant Vif as indicated. Virus infectivity was assessed as described in Fig. 1B.
doi:10.1371/journal.pone.0003963.g001
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against SIVagmgVif. HEK293T cells were transfected with
SIVagmgVif and with an A3C expression vector plus a control
vector, an expression vector for wild-type (WT) Vif, or a Vif mutant,
as indicated in Fig. 1B. Viruses were produced from the transfected
cells, and viral infectivity was tested in a standard Magi assay as
previously described [85,86]. WT Vif suppressed A3C and
maintained the infectivity of SIVagmgVif (Fig. 1B, column 2); this
level of viral infectivity in the presence of WT Vif was considered to
be 100% for comparison purposes. As expected, A3C dramatically
reduced theinfectivityofSIVagmgVifintheabsenceofVif(Fig.1B,
column 1). The Vif DR14/15AA and VifW79A mutants, which
have already been reported to be ineffective against A3F [79,81],
were unable to efficiently suppress the anti-viral activity of A3C
(Fig. 1B, columns 3 and 6). In contrast, the Vif K22E and VifRH41/
42AA mutants were able to suppress the anti-viral activity of A3C
(Fig. 1B, columns 4 and 5); as expected, these two mutant proteins
wereineffective insuppressing the anti-viral activity ofA3G (Fig. 1C,
columns 4 and 5).
Distinct HIV-1 Vif domains are required for A3C
degradation and virion exclusion
We also examined the effect of WT and mutant Vif molecules
on the expression and virion exclusion of A3C. For this purpose,
we transfected HEK293T cells with an A3C expression vector plus
a control vector (Fig. 2A, lane 1), WT Vif-myc expression vector
(lane 2), or one of the mutant vectors: VifDR14/15AA (lane 3),
VifK22E (lane 4), VifRH41/42AA (lane 5), or VifW79A (lane 6).
Consistent with the viral infectivity data (Fig. 1B), the intracellular
level of A3C was efficiently reduced in the presence of WT HIV-1
Vif (Fig. 2A, lane 2) when compared to the control vector (Fig. 2A,
lane 1). Mutant VifDR14/15AA (Fig. 2A, lane 3) and VifW79A
(Fig. 2A, lane 6) were less effective in reducing the stability of A3C
than was WT Vif (Fig. 2A, lane 2). Consequently, these two
mutants were also less effective in excluding A3C from virions
(Fig. 2C, lanes 3 and 6) than was the WT Vif (Fig. 2C, lane 2).
Mutant VifK22E and VifRH41/42AA did not produce any
significant decrease in the ability of Vif to alter A3C expression
(Fig. 2A, lanes 4 and 5) or virion exclusion (Fig. 2C, lanes 4 and 5).
Collectively, these results indicate that W79 and D14R15 of
HIV-1 Vif are important for Vif-mediated degradation of A3C, its
exclusion from virions, and the suppression of its anti-viral activity.
However, these residues were not important for Vif-mediated
degradation of A3G (Fig. 2B) or its exclusion from virions (Fig. 2D).
In contrast, K22 and R41H42 of HIV-1 Vif were important for
Vif-mediated degradation of A3G (Fig. 2B) and its exclusion from
virions, (Fig. 2D) but were dispensable for Vif-mediated A3C
degradation (Fig. 2A) and virion exclusion (Fig. 2C).
Figure 2. Effect of mutations in HIV-1 Vif on Vif activity against A3C and A3G. (A) Vif DR14/15 and W79 are required for A3C degradation.
HEK293T cells were cotransfected with A3C plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3C stability was
assessed by immunoblotting against A3C-HA, Vif-myc, and ribosomal p19 as a loading control. (B) Vif K22 and RH41/42 are required for A3G
degradation. HEK293T cells were cotransfected with A3G plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3G
stability was assessed as described in Fig. 2A. (C) Mutation of Vif DR14/15 and W79 inhibits Vif function, resulting in the packaging of A3C into SIV
virions. HEK293T cells were co-transfected with SIVagmTanDVif, A3C plus a control vector, WT Vif, or one of the indicated Vif mutants. Virus was
purified from the supernatant and evaluated for A3C packaging by immunoblotting with antibodies against A3C-HA and CAp27. (D) Mutation of Vif
K22 and RH41/42 inhibits Vif function, resulting in the packaging of A3G into HIV-1 virions. HEK293T cells were co-transfected with NL4-3DVif and
A3G plus a control vector, WT Vif, or one of the indicated Vif mutants. Virus was purified and evaluated by immunoblotting with antibodies against
A3G-HA and CAp24.
doi:10.1371/journal.pone.0003963.g002
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are also required for A3C binding
We then evaluated the interaction of WT and mutant Vif
molecules with A3C by co-immunoprecipitation analysis. HEK293T
cells were transfected with an A3C-HA expression vector plus a
control vector (Fig. 3A, lane 1) or an expression vector for WT Vif-
myc (lane 2), VifDR14/15AA-myc (lane 3), VifK22E-myc (lane 4),
VifRH41/42AA-myc (lane 5), or VifW79A-myc (lane 6). Vif-myc
proteins were immunoprecipitated from the cell lysates, and co-
precipitation of A3C-HA was detected by immunoblotting. WT Vif-
myc efficiently co-immunoprecipitated A3C-HA (Fig. 3B, lane 2); this
interaction was specific, since A3C-HA was not detected in the
absence of Vif (Fig. 3B, lane 1). Less A3C-HA was co-precipitated
with VifDR14/15AA-myc (Fig. 3B, lane 3) and VifW79A-myc
(Fig. 3B, lane 6) than with WT Vif-myc (Fig. 3B, lane 2), despite the
fact that A3C-HA levels were higher in cells expressing VifDR14/
15AA-myc (Fig. 3A, lane 3) and VifW79A-myc (Fig. 3A, lane 6) than
in those expressing WT Vif-myc (Fig. 3A, lane 2). These data suggest
that the impaired ability of the VifDR14/15AA and VifW79A
mutants to degrade and suppress A3C is due at least in part to their
reduced interaction with A3C. VifRH41/42AA-myc and VifK22E-
myc were able to efficiently interact with A3C-HA (Fig. 3B, lanes 4
and 5), as compared to the WT Vif-myc (Fig. 3B, lane 2).
Identification of the HIV-1 Vif regions required for A3DE
suppression
A3DE also has anti-HIV-1 activity and is neutralized by HIV-1
Vif. We next examined the ability of WT Vif and Vif mutant
molecules to affect A3DE expression (Fig. 4A).To this end, we
transfected HEK293T with the A3DE expression vector plus a
control vector (Fig. 4A, lane 1), the expression vector for WT Vif-
myc (lane 2), or one of the Vif mutant molecules (lanes 3, 4, 5, and
6). The intracellular level of A3DE was efficiently reduced by WT
Vif (Fig. 4A, lane 2) when compared to the vector control (Fig. 4A,
lane 1). As compared to WT Vif, VifDR14/15AA and VifW79A
were less effective in reducing A3DE expression (Fig. 4A, lanes 3
and 6). However, VifK22E and VifRH41/42AA preserved the
ability to reduce A3DE expression (Fig. 4A, lanes 4 and 5).
As expected, VifDR14/15AA and VifW79A (Fig. 4B, lanes 3 and
6) were less effective than WT (Fig. 4B, lane 2) in excluding A3DE
from HIV-1 virions. Mutant VifDR14/15AA and VifW79A also
showed a reduced ability to neutralize the anti-viral activity of A3DE
(Fig. 4C, columns 3 and 6) when compared to the WT Vif (Fig. 4C,
column 2). Mutant VifK22E and VifRH41/42AA were as effective
as WT Vif (Fig. 4B) in excluding A3DE from virions, and they could
efficiently counteract the anti-viral activity of A3DE (Fig. 4C). These
data indicate that the residues of HIV-1 Vif that are important for
A3F and A3C suppression are also important for A3DE suppression.
Conversely, the residues of HIV-1 Vif that are important for A3G
suppression are dispensable for A3DE suppression.
We also evaluated the interaction of WT and Vif mutant
molecules with A3DE by co-immunoprecipitation analysis.
HEK293T cells were transfected with an A3DE expression vector
plus a control vector (Fig. 5A, lane 1) or the expression vector for
Figure 3. The D
14RMR
17 and Trp79 domains mediate the
interaction between HIV-1 Vif and A3C. Vif DR14/15 and W79
showed reduced interaction with A3C when compared to WT Vif.
HEK293T cells were cotransfected with A3C and the control vector, HIV-
1 Vif, or one of the indicated Vif mutants. At 48 h post-transfection, cell
lysates were prepared and immunoprecipitated with anti-myc antibody
and agarose-conjugated protein A/G. Cell lysate (A) and the interaction
of A3C with WT or mutant Vif molecules(B) were detected by
immunoblotting with antibodies against A3G-HA and Vif-myc.
doi:10.1371/journal.pone.0003963.g003
Figure 4. Effect of mutation of HIV-1 Vif on its activity against
A3DE. (A) Vif DR14/15 and W79 are required for A3DE degradation.
HEK293T cells were cotransfected with A3DE plus a control vector, HIV-1
Vif, or one of the indicated Vif mutant expression vectors. A3DE stability
was assessed as described in Fig. 2A. (B) Mutation of Vif DR14/15 and W79
inhibits Vif function, resulting in the packaging of A3DE into HIV-1 virions.
HEK293T cells were co-transfected with NL4-3DVif and A3DE plus a
control vector, WT Vif, or one of the indicated mutant expression vectors.
Virus was purified and evaluated for A3DE packaging as described in
Fig.2D.(C)Effect ofWTormutantVifontheinfectivityofNL4-3gVifinthe
presence of A3DE. HIV viruses were produced in HEK293T cells
coexpressing A3DE in the presence of WT or mutant Vif as indicated.
Virus infectivity was assessed as described in Fig. 1B.
doi:10.1371/journal.pone.0003963.g004
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(lane 4), VifRH41/42AA-myc (lane 5), or VifW79A-myc (lane 6).
The myc-tagged Vif proteins were immunoprecipitated from cell
lysates and the co-precipitation of A3DE was assessed by
immunoblotting. A3DE-HA was efficiently co-immunoprecipitated
with WT Vif-myc (Fig. 5B, lane 2), and this interaction was specific,
since A3DE-HA was not precipitated in the absence of Vif (Fig. 5B,
lane 1). Even though higher levels of A3DE were detected in cells
expressing VifDR14/15AA (Fig. 5B, lane 3) and VifW79A (Fig. 5B,
lane 6) than in those expressing WT Vif, significantly less A3DE was
immunoprecipitated with VifDR14/15AA and VifW79A than with
WT Vif. When intracellular level of A3DE was considered,
VifDR14/15AA and VifW79A had 5–10 fold reduced ability to
interact with A3DE compared to the WT Vif. Thus, the impaired
ability of VifDR14/15AA and VifW79A to degrade A3DE could be
attributed, at least in part, to their reduced recognition of A3DE.
The carboxyl-terminal deamination domain of A3F
behaves like the full-length A3F in terms of Vif sensitivity
HIV-1 Vif utilizes similar regions to interact with A3C, A3DE,
and A3F. It is interesting to note that HIV-1 Vif suppresses the
single-domain cytidine deaminase A3C and the double-domain
enzyme A3F through similar means. This result raises the question
of whether HIV-1 Vif recognizes the amino- or carboxyl- terminal
domain of A3F. Alignment analysis of A3C and A3F showed that
there is a strikingly higher degree of homology (77%) between
A3C and the carboxyl-terminal domain of A3F (Fig. 6A) than with
the amino-terminal domain of A3F (47%, Fig. 6B).
To determine whether the carboxyl-terminal domain of A3F
alone can interact with HIV-1 Vif, we constructed an expression
vector for the HA epitope-tagged carboxyl-terminal domain of A3F
(amino acids 190–373). HEK293T cells were co-transfected with
expression vectors for HIV-1 Vif-myc plus a control vector or either
full-length A3F-HA or the carboxyl terminal A3F-C-HA. The A3F-
HA and A3F-C-HA proteins were immunoprecipitated from
transfected cell lysates with anti-HA antibody conjugated to agarose
beads. Both full-length A3F-HA and A3F-C-HA (Fig. 6C, lanes 5
and 6) efficiently co-immunoprecipitated Vif-myc. Vif-myc was not
co-immunoprecipitated in the absence of any A3F proteins (Fig. 6B,
lane 4), indicating the specificity of the assay system.
Since the carboxyl-terminal domain of A3F alone could interact
with HIV-1 Vif, we asked whether the A3F-C alone could be
degraded by HIV-1 Vif. HEK293T cells were transfected with an
expression vector for A3F-C-V5 plus a control vector (Fig. 6D, lane
1), the expression vector for WT Vif-myc (lane 2), or one of various
Vif mutants, as indicated (lane 3, 4, 5, and 6). The intracellular level
of A3F-C-V5 was efficiently reduced by WT Vif (Fig. 6D, lane 2)
when compared to the vector control (Fig. 6D, lane 1). However,
VifDR14/15AA and VifW79A showed an impaired ability to reduce
A3F-C-V5 expression (Fig. 6D, lanes 3 and 6) when compared to WT
Vif. VifK22E and VifRH41/42AA retained their ability to degrade
A3F-C-V5 (Fig. 6D, lanes 4 and 5). These data indicate that the
requirement for the degradation of full-length A3F is the same as for
the degradation of the carboxyl-terminal domain of A3F.
Discussion
Human APOBEC3 cytidine deaminases are either single-
domain or double-domain proteins. Regions in the double-domain
A3G protein that are important for HIV-1 Vif-mediated
degradation have been shown to span both the amino- and the
carboxyl-terminal domains of A3G. Conticello et al. has demon-
strated that amino acids 54–124 of A3G alone can interact with
HIV-1 Vif [68]. Residues D128 and D130 were later reported to
be important for HIV-1 Vif binding as well [87–91]. More
recently, Zhang et al. have demonstrated that although amino
acids 1–156 of A3G are sufficient for the interaction with HIV-1
Vif, additional regions spanning amino acids 105–245 are required
for HIV-1 Vif-mediated polyubiquitination and degradation [85].
Thus, the amino-terminal domain of A3G mediates its interaction
with HIV-1 Vif, but both cytidine deamination domains of A3G
are involved in Vif-mediated degradation.
We have now found that, unlike the case for A3G, the carboxyl-
terminal domain alone of another double-domain protein, A3F, is
sufficient for the interaction with HIV-1 Vif, and, more
importantly, is all that is required for A3F to undergo Vif-
mediated degradation. These new data regarding the degradation
of A3F are consistent with our previous observations that the
carboxyl- but not the amino-terminal domain of A3F is important
for its functional interaction with HIV-1 Vif [71,79]. Mutation of
the aspartate residue, D128, in the amino-terminal domain of
A3G has been shown to influence its recognition by HIV-1 Vif
[87–89]. The analogous residue in A3F, E127, is not important for
HIV-1 Vif binding [71], and modifications of this amino acid in
human A3F do not change its recognition by HIV-1 Vif or
SIVagm Vif [71]. Furthermore, while C-terminal tag modifica-
tions of A3F (HA-tag vs V5-tag) can significantly influence its
ability to be degraded by HIV-1 Vif, the same modifications of
A3G do not affect its ability to be recognized by HIV-1 Vif [79].
Here we also provide evidence that Vif-mediated degradation of
the carboxyl-terminal domain of A3F is similar to that of full-length
A3F.WeandothershaveidentifieduniqueregionsinHIV-1Vifthat
are critical for A3G, but not A3F, degradation and vice versa
[13,67,78–83]. For example, W11, D14, R15, and W79 of HIV-1
Figure 5. The D
14RMR
17 and Trp79 domains mediate the
interaction between Vif and A3DE. HIV-1 Vif DR14/15 and W79 all
showed reduced interaction with A3DE when compared to WT Vif.
HEK293T cells were cotransfected with A3DE and a control vector, WT
Vif, or one of the indicated Vif mutants. At 48 h post-transfection, cell
lysates were prepared and immunoprecipitated with anti-myc antibody
and agarose-conjugated protein A/G. Cell lysates (A) and the interaction
of A3C with WT or mutant Vif molecules(B) were detected by
immunoblotting with antibodies against A3DE-HA and Vif-myc.
doi:10.1371/journal.pone.0003963.g005
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the other hand, K22, R41, and H42 of HIV-1 Vif are required for
A3G but not A3F binding and degradation. Residues such as
D14R15 and W79 in HIV-1 Vif that are important for full-length
A3F binding and degradation are also important for Vif-mediated
degradation of the carboxyl-terminal domain of A3F. On the other
hand, residues such as K22 and R41H42 that are important for the
Vif-mediated degradation of A3G are dispensable for Vif-mediated
degradation of both full-length A3F and the carboxyl-terminal
domain of A3F. These data indicate the carboxyl-terminal domain
of A3F is the main target of HIV-1 Vif against A3F.
Our data also demonstrate that the N-terminal region of HIV-1
Vif mediates its binding not only to the target molecules A3G and
A3F but also to A3C and A3DE. Interestingly, we found that the
single-domain cytidine deaminase A3C is also recognized and
degraded by HIV-1 Vif through a mechanism similar to that for
A3F. The residues in HIV-1 Vif that are important for A3F
interaction and degradation were also important for Vif-mediated
degradation of A3C. In contrast, those that are mainly important
for the Vif-mediated degradation of A3G were found to be
dispensable for Vif-mediated degradation of A3C. A3C has a high
degree of amino acid homology to the carboxyl-terminal domain
of A3F. However, unlike A3F, A3C has only weak anti-HIV-1
function [16,18]. It is not clear whether HIV-1 Vif has evolved to
disable A3F, and its ability to suppress A3C is merely an incidental
consequence of the high degree of homology between A3C and
the carboxyl-terminal domain of A3F. Whether A3C has anti-
HIV-1 activity in certain HIV-1 natural target cells in vivo is an
open question.
Consistent with a previous report [72], we found that A3DE has
substantial anti-HIV-1 activity (Fig. 4). This protein is expressed in
peripheral blood mononuclear cells [72] and macrophages (data
not shown). Sequence alignment of A3DE and A3F shows a high
degree of homology between these two molecules, and HIV-1 Vif
residues required for A3F binding and suppression are also
essential for A3DE binding and suppression (Figs. 4 and 5).
Collectively, our data suggest that Vif employs distinct protein
interfaces to recognize various human APOBEC3 proteins (Fig. 7).
Figure 6. The C-CCD of A3F behaves like the full-length A3F. (A) Alignment of A3C and the C-CCD of AF. (B) Alignment of A3C and the N-CCD
of AF. (C) Interaction of A3F and A3F-C with HIV-1 Vif. HEK293T cells were cotransfected with HIV-1 Vif-myc plus control vector, full-length A3F-HA, or
A3F-C-HA. The cells were treated with 10 mM MG132 12 h prior to harvesting., and A3F-HA proteins were immunoprecipitated from cell lysates with
an anti-HA antibody conjugated to agarose beads. The interaction of A3F with HIV-1 Vif molecules was detected by immunoblotting with antibodies
against A3F-HA and Vif antibody. (D) HIV-1 Vif induces the degradation of the C-CCD of A3F. HEK293T cells were transfected with an expression
vector encoding the C-CCD of A3F plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3F-C stability was assessed by
immunoblotting with antibodies against V5, Vif-myc, and b-tubulin as a loading control.
doi:10.1371/journal.pone.0003963.g006
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mechanism that is distinct from that for A3G (Fig. 7). The
W
11xxDRMR
17 and T
74GERxW
79 motifs of HIV-1 Vif are
dispensable for the suppression of the potent anti-HIV-1 cytidine
deaminase A3G yet are highly conserved among diverse HIV-1
strains. It is an open question whether these motifs have been
conserved onlyforthesuppressionofA3Forwhethertheyhavebeen
evolutionarily selected to target other human cytidine deaminases,
such A3C and A3DE, as well. The highly conserved nature of these
residues in diverse HIV-1 Vif molecules indicates that A3F, A3C,
and/or A3DE represent a selection force against HIV-1 in vivo.T h i s
argument would be consistent with the in vivo observation of HIV-1
G-to-Amutationpatterns.GA-to-AAmutations(apatterngenerated
by A3F, A3C, and/or A3DE) are frequently detected in viral
sequences recovered from HIV-1-infected individuals [20]. The
highly conserved residues inVif that are required for the suppression
of multiple human cellular anti-HIV-1 factors represent another
potential drug target against HIV-1.
Materials and Methods
Plasmid construction
The infectious molecular clone of the Vif mutant pNL4-3DVif
construct was obtained from the AIDS Research Reagents
Program, Division of AIDS, National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH).
The SIVagmTanDVif construct was prepared by inserting four
nucleotidesinto the Age site inthe Vif coding region of pSIVagmTan-
1. VR1012, pHIV-1Vif-myc, pA3G-HA, and pA3F-HA have been
previously described [62]. The A3C HA-tagged expression plasmid
was a kind gift from Dr Michael Malim (Guy’s, King’s, and St.
Thomas’ School of Medicine, King’s College, London). A3DE was a
generous gift of Dr Y.H. Zheng (Biomedical and Physical Sciences,
Michigan State University). Plasmids pVifDR14/15AA, pVifK22E,
pVifRH41/42AA, and pVifW79A, were made from pHIV-1Vif-
myc by site-directed mutagenesis. A3F-C-HA was amplified with the
following primers: forward 59- GTACGTCGACGCC ATG AAC-
CCGATGGAGGCAATGTATC-39,r e v e r s e5 9- GTACGCGG-
CCGCTCACGCGTAATCTGGGACGTCGTAAGGGTACTC-
GAGAATCTCCTGCAGCTTG -39 containing SalIa n dNotI sites,
respectively, and a C-terminal HA tag. The PCR product was
cloned into VR1012 to generate A3F-C-HA. A3F-C-V5 was
constructed with the above forward primer and the reverse primer
59- GTACGCGGCCGCTCACGTAGAATCGAGACCGAGGA-
GAGGGTTAGGGATAGGCTTACC CTCGAGAATCTCCT-
GCAGCTTG-39 containing SalIa n dNotIs i t e s ,r e s p e c t i v e l y ,a n da
C-terminal V5 tag. The PCR product was cloned into VR1012 to
generate A3F-C-V5.
Cell culture, transfection, viral infectivity (MAGI) assays,
APOBEC3 degradation, and antibodies
HEK293T and MAGI-CCR5 (AIDS Research Reagents
Program) cells were maintained and transfected or infected as
previously described [62]. Transfection was performed with
Lipofectamine2000 (Invitrogen) as instructed by the manufacturer.
Viral infectivity (MAGI assays) were performed as described
[62]:Virus was produced by transfecting HEK293T cells in a six-
well plate with 1 mg of NL4-3gVif or SIVagmTanDVif, 1 mgo f
wild-type or mutant Vif, and 0.3 mg of APOBEC3 as indicated.
Virus was harvested from the supernatant for viral infectivity
assays, and cell lysates were prepared for immunoblotting.
Infectivity was assessed at 48 h post-infection and normalized to
the input CAp24 or CAp27. The antibodies used in this study
have been previously described [84]: anti-HA antibody, anti-myc
antibody, anti-Vif (AIDS Research Reagents Program), and anti-
human ribosomal P antigens. The anti-Vif antibody was obtained
from the AIDS Research Reagents Program (2221), the mouse
anti-V5 antibody from Invitrogen (R96025), and the mouse anti-
tubulin antibody from Covance (MMS-410P).
Immunoprecipitation and immunoblot analysis
A T-25 flask of HEK293T cells was transfected with 3 mg
APOBEC3 plus 3 mg of wild-type or mutant Vif expression vectors
as indicated. Cells were harvested, washed twice with cold PBS
and lysed in lysis buffer (50 mM Tris–HCl [pH 7.5] with 150 mM
NaCl, 1% [v/v] Triton X-100, and complete protease inhibitor
cocktail tablets) at 4uC for 1 h, then centrifuged at 10,000g for 30
min. For myc-tag immunoprecipitation, pre-cleared cell lysates
were mixed with anti-myc antibody (Upstate) and incubated with
protein G beads at 4uC for 3 h. For HA tag immunoprecipitation,
pre-cleared cell lysates were mixed with anti-HA antibody-
conjugated agarose beads (Roche) and incubated at 4uC for 3 h.
Samples were then washed three times with washing buffer (20
mM Tris–HCl [pH 7.5], with 100 mM NaCl, 0.1 mM EDTA,
and 0.05% [v/v] Tween-20). The beads were eluted with elution
buffer (0.1 M glycine–HCl, pH 2.0), and 26 loading buffer was
added. The eluted materials were then analyzed by SDS-PAGE
and immunoblotting with the anti-myc antibody or the anti-HA
antibody as described.
Figure 7. Models of HIV-1 Vif mediated interaction and
polyubiquitination of A3G (A) and A3F (B). (A) Two distinct
domains of HIV-1 Vif (G-box and FG-box) mediate interaction with the
amino-terminal domain of A3G. However, the carboxyl-terminal domain
of A3G is also required for Vif-mediated polyubiquitination and
degradation. (B) Three distinct domains of HIV-1 Vif (F1-box, F2-box,
and FG-box) mediate interaction with the carboxyl-terminal domain of
A3F. The carboxyl-terminal domain of A3F is sufficient for Vif-mediated
A3F degradation.
doi:10.1371/journal.pone.0003963.g007
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